A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico
Biotechnology and Applied Biochemistry · 2025
DOI: 10.1002/bab.2646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2025. Verfasst von Shirin Mahmoodi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran. Hauptthemen laut MEDLINE: Ebolavirus, Vaccines, Subunit, Monkeypox virus, Antigens, Viral. Die Arbeit nennt 106 Literaturangaben.
Abstract (Originalsprache)
The emergence or reemergence of monkeypox (Mpox) and Ebola virus (EBOV) agents causing zoonotic diseases remains a huge threat to human health. Our study aimed at designing a multi‐epitope vaccine (MEV) candidate to target both the Mpox and EBOV agents using immunoinformatics tools. Viral protein sequences were retrieved, and potential nonallergenic, nontoxic, and antigenic epitopes were obtained. Next, cytotoxic and helper T‐cell (CTL and HTL, respectively) and B‐cell (BCL) epitopes were predicted, and those potential epitopes were fused utilizing proper linkers. The in silico cloning and expression processes were implemented using Escherichia coli K12. The immune responses were prognosticated using the C‐ImmSim server. The MEV construct (29.53 kDa) included four BCL, two CTL, and four HTL epitopes and adjuvant. The MEV traits were pertinent in terms of antigenicity, non‐allergenicity, nontoxicity, physicochemical characters, and stability. The MEV candidate was also highly expressed in E. coli K12. The strong affinity of MEV‐TLR3 was confirmed using molecular docking and molecular dynamics simulation analyses. Immune simulation analyses unraveled durable activation and responses of cellular and humoral arms alongside innate immune responses. The designed MEV candidate demonstrated appropriate traits and was promising in the prediction of immune responses against both Mpox and EBOV agents. Further experimental assessments of the MEV are required to verify its efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran.
- Department of Plant Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
ORCID-Profile: Shirin Mahmoodi, Abdolmajid Ghasemian
Zitieren
APA
Mahmoodi, S., Amirzakaria, J. Z., & Ghasemian, A. (2025). A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2646
Vancouver
Mahmoodi S, Amirzakaria JZ, Ghasemian A. A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.2646
BibTeX
@article{Mahmoodi2025,
author = {Mahmoodi, Shirin and Amirzakaria, Javad Zamani and Ghasemian, Abdolmajid},
title = {A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico},
journal = {Biotechnology and Applied Biochemistry},
year = {2025},
doi = {10.1002/bab.2646}
}
EUVIMED